Press release
Lewy Body Dementia Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032), States DelveInsight | Eisai, EIP Pharma, Sun Pharma, Axovant Sciences Ltd., Cognition
DelveInsight's "Lewy Body Dementia Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Lewy Body Dementia, historical and forecasted epidemiology as well as the Lewy Body Dementia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Lewy Body Dementia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Lewy Body Dementia Market Forecast [https://www.delveinsight.com/sample-request/lewy-body-dementia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key facts of the Lewy Body Dementia Market Report:
* The Lewy Body Dementia market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
* In August 2023, EIP Pharma, headquartered in the United States, has administered the initial dose to the first patient in its RewinD-LB clinical trial, investigating neflamapimod for the management of individuals with dementia with Lewy bodies (DLB). Building upon positive results from a Phase IIa trial, AscenD-LB, the biopharmaceutical company has initiated its Phase IIb trial (NCT05869669) of neflamapimod (also known as VX-745).
* The condition typically lasts between 5 and 7 years from the time of diagnosis until death, but it can last anywhere between 2 and 20 years
* Age is thought to be the biggest risk factor. The majority of those who get the condition are above 50. There is no known lifestyle factor that increases a person's risk for Lewy Body Dementia
* In order to free dementia with Lewy bodies (DLB) from the influence of approved treatments, Cognition Therapeutics has been working hard. 120 adults with DLB, aged 50 to 80, are participating in a phase 2, double-blind, placebo-controlled research (NCT0522514) that is evaluating the company's investigational drug, CT1812. The project, which is funded by a $30 million grant from the National Institute on Ageing of the National Institutes of Health, will evaluate safety results as well as adjustments in cognitive function, physical activity, and pharmacokinetic and pharmacodynamic biomarkers
* Key Lewy Body Dementia Companies: Eisai, EIP Pharma, Sun Pharma, Axovant Sciences Ltd., Cognition Therapeutics, Cephalon, Athira Pharma, Ortho-McNeil Neurologics, Inc., H. Lundbeck A/S, Axovant Sciences Ltd., GE Healthcare, Aptinyx, NeuroActiva, Inc., CuraSen Therapeutics, Inc., ACADIA Pharmaceuticals Inc., and others
* Key Lewy Body Dementia Therapies: E2027, Neflamapimod, K0706, RVT-101, CT1812, K0706, Irsenontrine, Donepezil, ATH-1017, Galantamine, Memantine, Nelotanserin, DatSCAN, NYX-458, N-831(Traneurocin), CST-103, CST-107, Pimavanserin, and others
* The Lewy Body Dementia epidemiology based on gender analyzed that through various secondary studies it can be found that LBD more commonly affects males than females
* The Lewy Body Dementia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Lewy Body Dementia pipeline products will significantly revolutionize the Lewy Body Dementia market dynamics.
Lewy Body Dementia Overview
The National Institute of Health (NIH) describes Lewy body dementia (LBD) as a condition characterised by aberrant accumulations of the protein alpha-synuclein in the brain. These deposits, also known as Lewy bodies, modify certain brain chemicals, and these modifications can result in issues with thought, movement, behaviour, and mood. One of the most prevalent types of dementia is Lewy body dementia.
Get a Free sample for the Lewy Body Dementia Market Report
https://www.delveinsight.com/report-store/lewy-body-dementia-market [https://www.delveinsight.com/report-store/lewy-body-dementia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Lewy Body Dementia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Lewy Body Dementia Epidemiology Segmentation:
The Lewy Body Dementia market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
* Total Prevalence of Lewy Body Dementia
* Prevalent Cases of Lewy Body Dementia by severity
* Gender-specific Prevalence of Lewy Body Dementia
* Diagnosed Cases of Episodic and Chronic Lewy Body Dementia
Download the report to understand which factors are driving Lewy Body Dementia epidemiology trends @ Lewy Body Dementia Epidemiology Forecast [https://www.delveinsight.com/sample-request/lewy-body-dementia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Lewy Body Dementia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Lewy Body Dementia market or expected to get launched during the study period. The analysis covers Lewy Body Dementia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Lewy Body Dementia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Lewy Body Dementia Therapies and Key Companies
* E2027: Eisai
* Neflamapimod: EIP Pharma
* K0706: Sun Pharma
* RVT-101: Axovant Sciences Ltd.
* CT1812: Cognition Therapeutics
* K0706: Cephalon
* Irsenontrine: Eisai Inc.
* Neflamapimod: EIP Pharma Inc
* Donepezil: Eisai Co., Ltd.
* ATH-1017: Athira Pharma
* Galantamine: Ortho-McNeil Neurologics, Inc.
* Memantine: H. Lundbeck A/S
* Nelotanserin: Axovant Sciences Ltd.
* DatSCAN: GE Healthcare
* NYX-458: Aptinyx
* N-831(Traneurocin): NeuroActiva, Inc.
* CST-103, CST-107: CuraSen Therapeutics, Inc.
* Pimavanserin: ACADIA Pharmaceuticals Inc.
Discover more about therapies set to grab major Lewy Body Dementia market share @ Lewy Body Dementia Treatment Market [https://www.delveinsight.com/sample-request/lewy-body-dementia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Lewy Body Dementia Market Strengths
* Increasing research and development to understand the diversity of the disease might improve the diagnosis of LBD thereby resulting in a lucrative market opportunity.
* Current treatments are effective in relieving the symptoms and improving the quality of life of the patients.
Lewy Body Dementia Market Opportunities
* Several organizations are actively working to provide information and increase awareness of such disorders.
* There is only one approved treatment option for LBD which opens a platform of new therapies to boost the market ofLBD.
* The pipeline for PMM is narrow as there is limited R&D activity
Scope of the Lewy Body Dementia Market Report
* Study Period: 2019-2032
* Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
* Key Lewy Body Dementia Companies: Eisai, EIP Pharma, Sun Pharma, Axovant Sciences Ltd., Cognition Therapeutics, Cephalon, Athira Pharma, Ortho-McNeil Neurologics, Inc., H. Lundbeck A/S, Axovant Sciences Ltd., GE Healthcare, Aptinyx, NeuroActiva, Inc., CuraSen Therapeutics, Inc., ACADIA Pharmaceuticals Inc., and others
* Key Lewy Body Dementia Therapies: E2027, Neflamapimod, K0706, RVT-101, CT1812, K0706, Irsenontrine, Donepezil, ATH-1017, Galantamine, Memantine, Nelotanserin, DatSCAN, NYX-458, N-831(Traneurocin), CST-103, CST-107, Pimavanserin, and others
* Lewy Body Dementia Therapeutic Assessment: Lewy Body Dementia current marketed and Lewy Body Dementia emerging therapies
* Lewy Body Dementia Market Dynamics: Lewy Body Dementia market drivers and Lewy Body Dementia market barriers
* Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
* Lewy Body Dementia Unmet Needs, KOL's views, Analyst's views, Lewy Body Dementia Market Access and Reimbursement
To know more about Lewy Body Dementia companies working in the treatment market, visit @ Lewy Body Dementia Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/lewy-body-dementia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Lewy Body Dementia Market Report Introduction
2. Executive Summary for Lewy Body Dementia
3. SWOT analysis of Lewy Body Dementia
4. Lewy Body Dementia Patient Share (%) Overview at a Glance
5. Lewy Body Dementia Market Overview at a Glance
6. Lewy Body Dementia Disease Background and Overview
7. Lewy Body Dementia Epidemiology and Patient Population
8. Country-Specific Patient Population of Lewy Body Dementia
9. Lewy Body Dementia Current Treatment and Medical Practices
10. Lewy Body Dementia Unmet Needs
11. Lewy Body Dementia Emerging Therapies
12. Lewy Body Dementia Market Outlook
13. Country-Wise Lewy Body Dementia Market Analysis (2019-2032)
14. Lewy Body Dementia Market Access and Reimbursement of Therapies
15. Lewy Body Dementia Market Drivers
16. Lewy Body Dementia Market Barriers
17. Lewy Body Dementia Appendix
18. Lewy Body Dementia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=lewy-body-dementia-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20232032-states-delveinsight-eisai-eip-pharma-sun-pharma-axovant-sciences-ltd-cognition]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lewy Body Dementia Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032), States DelveInsight | Eisai, EIP Pharma, Sun Pharma, Axovant Sciences Ltd., Cognition here
News-ID: 3462182 • Views: …
More Releases from ABNewswire
Schneider Electric outperforms 2023 sustainability targets and maintains its lea …
Schneider Electric, the leader in the digital transformation of energy management and automation, announced today its 2023 sustainability impact performance as part of its full-year financial results. The Schneider Sustainability Impact score for the year exceeded expectations, reaching 6.13 out of 10, and surpassing the year-end target of 6 out of 10. Schneider Electric was also recognized as a top performer by independent environmental, social, and governance (ESG) ratings throughout…
Sustainability Business Division of Schneider Electric Responds to Cybersecurity …
- Incident limited to Sustainability Business division
- No impact on any other Schneider Electric entity
- Access to business platforms reopened on January 31, 2024
- Certain data from Sustainability Business was obtained by threat actor
Note: the following statement was published on January 29, 2024, and updated on Feb. 1st and Feb. 19th, 2024. Latest update was issued to inform that certain data from Sustainability Business was obtained by the threat actor.
On…
Schneider Group-owned Lauritz Knudsen to invest Rs 850 crore in 3 years
L&T Switchgear, the electrical and automation arm of L&T, which Schneider Electric acquired in 2020, is rebranded as Lauritz Knudsen
Lauritz Knudsen, owned by Schneider Electric Group, aims to strategically invest approximately Rs 850 crore over the next three years to establish itself as a significant player in India's rapid growth trajectory in the electrical sector.
In 2020, Schneider Electric acquired L&T Switchgear, Larsen & Toubro's electrical and automation business, for Rs…
Schneider Electric launches EcoStruxure Trademark Plant Lean Management boosting …
- New, ready-to-use solution speeds up industrial digitalization.
- Plant data empowers shop floor workers and improves site performance.
- Hardware agnostic software runs on AVEVA Trademark Data Hub platform.
Schneider Electric, the leader in the digital transformation of energy management and automation, today launched EcoStruxure Plant Lean Management, a digital solution that collects and aggregates data across industrial operations to develop key performance indicators (KPIs) for short interval management (SIM) meetings, where…
More Releases for Lewy
Antipsychotic Drugs For Lewy Body Dementia Treatment Market Forecast and Trends …
Lewy Body Dementia Treatment Market size is done based on a triangulation methodology that is primarily based on experimental modelling approaches such as patient-level data or disease epidemiology for any key indications , number of procedures and install base analysis for any equipment to obtain precise market estimations for the base year as well as in historic data analysis.
Bottom-up approach is always used to obtain Lewy Body Dementia…
Lewy Body Dementia Drugs Market Opportunities And Analysis By Size, Share, Trend …
The global Lewy Body Dementia Drugs market 2020 research is a professional and in-depth study on the current state of the industry and provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Lewy Body Dementia Drugs market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well…
Lewy Body Dementia Therapeutics - Pipeline Analysis 2018, Clinical Trials & Resu …
Lewy body dementia is a progressive brain disorder in which Lewy bodies build up in different parts of the brain that regulate cognition, movement and behavior. Lewy bodies are abnormal deposition of a protein called alpha-synuclein.
Download the sample report @ https://www.pharmaproff.com/request-sample/1104
The symptoms associated with the Lewy body dementia includes memory and thinking problems; moving problems; and sleeping and behavioral changes. It can be treated by medications, physical therapy, speech…
Lewy Body Dementia Treatment Market Driven by Surging Cholinesterase Inhibitor S …
According to a latest research study by Fact.MR the global lewy body dementia treatment market is projected to surpass US$ 3,650 Mn in 2019, up from nearly 3,500 Mn in 2018. Broader factors concerning the healthcare industry, especially renewed focus on managing geriatric and mental health issues, are likely to impact growth of lewy body dementia treatment market.
Cholinesterase inhibitors will remain the topselling drugs for treating lewy body dementia, accounting…
Global Lewy Body Dementia Treatment Market: Moving Towards a Brighter Future
Qyresearchreports include new market research report Global Lewy Body Dementia Treatment Market Research Report 2018 to its huge collection of research reports.
The Global Lewy Body Dementia Treatment market has been thoroughly studied, researched and detailed on in this publication by taking the assistance of advanced secondary and primary research that has been performed by the best of analysts and by making use of the best of the available techniques. The…
Asia-Pacific Lewy Body Dementia Treatment Market Moving Towards a Brighter Futur …
Worldwide Market Reports added Latest Research Report titled ” Asia-Pacific Lewy Body Dementia Treatment Market Report 2018 ” to its Large Report database.
In this report, the Asia-Pacific Lewy Body Dementia Treatment market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025.
Geographically, this report split Asia-Pacific into several key…
